What aging clocks can learn from clinical trials
Biological aging clocks are among the most discussed tools in longevity science. But how well do they perform as measuring sticks in real clinical trials testing aging interventions? A new analysis digs into existing trial data and finds a more complicated picture.
Biological aging clocks are mathematical models that estimate how old someone is biologically, based on body data that changes with age. That can include genetic or molecular data (omics data), but also simple blood test results or medical imaging. The researchers examined what existing clinical trial data can reveal about the value of these clocks as endpoints in longevity studies.
What do aging clocks actually measure?
A clock is calibrated on a reference population: it learns to predict how old someone is. When applied to people outside that population, it tends to predict a higher biological age for those most affected by aging. A higher clock age correlates, at the population level, with greater mortality risk and more age-related conditions.
But that population-level correlation does not automatically translate into usefulness inside a clinical trial. If you test an intervention and the clock does not move, does that mean the intervention is not working? Or that the clock is not sensitive to that type of change? That distinction is critical and difficult to resolve.
What existing trial data show
The analysis finds that clocks respond inconsistently to known interventions. Some clocks show movement with certain treatments; others do not. This makes it difficult to treat clocks as reliable endpoints in longevity trials right now. The authors emphasise that more clarity is needed on which clock measures which aspect of the aging process.
For longevity research, this is an important methodological point. Clocks are promising tools, but they are not yet validated measures of what an intervention truly does to the aging process. The analysis comes from Fight Aging!, which explicitly aims to make aging medically controllable. It reads as a call to the field to refine its measurement tools before clocks serve as primary endpoints in pivotal trials.
Want to research this yourself?
Search terms: biological aging clock validation clinical trial, omics data aging endpoint, epigenetic clock intervention study